Další formáty:
BibTeX
LaTeX
RIS
@article{1137343,
author = {Rektor, Ivan},
article_location = {LONDON},
article_number = {2},
doi = {http://dx.doi.org/10.1517/14656566.2013.754883},
keywords = {AMPA receptor antagonist; anticonvulsant agent; partial-onset seizures; perampanel; refractory epilepsy},
language = {eng},
issn = {1465-6566},
journal = {EXPERT OPINION ON PHARMACOTHERAPY},
title = {Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures},
url = {http://informahealthcare.com/doi/abs/10.1517/14656566.2013.754883?journalCode=eop},
volume = {14},
year = {2013}
}
TY - JOUR
ID - 1137343
AU - Rektor, Ivan
PY - 2013
TI - Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures
JF - EXPERT OPINION ON PHARMACOTHERAPY
VL - 14
IS - 2
SP - 225-235
EP - 225-235
PB - INFORMA HEALTHCARE
SN - 14656566
KW - AMPA receptor antagonist
KW - anticonvulsant agent
KW - partial-onset seizures
KW - perampanel
KW - refractory epilepsy
UR - http://informahealthcare.com/doi/abs/10.1517/14656566.2013.754883?journalCode=eop
L2 - http://informahealthcare.com/doi/abs/10.1517/14656566.2013.754883?journalCode=eop
N2 - Introduction: In the search for new antiepileptic drugs (AEDs), AMPA-type receptor antagonists have a novel target and the potential to improve seizure control in patients with refractory seizures. This article reviews preclinical and clinical data for 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile, perampanel, a new chemical entity developed for the treatment of partial-onset seizures. Areas covered: Perampanel is a selective, non-competitive AMPA receptor antagonist. The preclinical profile of perampanel and its clinical development are reviewed. Expert opinion: Unlike many traditional AEDs, perampanel demonstrated efficacy in a broad spectrum of preclinical seizure models. Phase I and II clinical studies suggested perampanel had a favorable safety and tolerability profile and demonstrated proof of concept for its mechanism of action in patients with treatment-resistant partial-onset seizures. Three Phase III studies have additionally demonstrated that adjunctive perampanel 4 - 12 mg/day is well-tolerated and significantly improves seizure control in these patients. Median reductions in seizure frequency were 23.3% (4 mg), 26.3 - 30.8% (8 mg) and 17.6 - 34.5% (12 mg) versus 9.7 - 21.0% for placebo. Responder rates were 28.5% (4 mg), 33.3 - 37.6% (8 mg) and 33.9 - 36.1% (12 mg) versus 14.7 - 26.4% for placebo. Perampanel may offer an alternative treatment option in the management of patients with refractory partial-onset seizures.
ER -
REKTOR, Ivan. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. \textit{EXPERT OPINION ON PHARMACOTHERAPY}. LONDON: INFORMA HEALTHCARE, roč.~14, č.~2, s.~225-235. ISSN~1465-6566. doi:10.1517/14656566.2013.754883. 2013.
|
